June 25, 2018 Uncategorized

Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy

Basel, 25 June 2018 Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer... Read more

June 22, 2018 PR/Corporate

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 22 June 2018 Changes to the Roche Enlarged Corporate Executive Committee Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Sophie Kornowski-Bonnet, Head of Roche Partnering and member of the enlarged Corporate Executive Committee since 2012, has accepted a new opportunity and will be leaving the company effective 31 July 2018. James Sabry, MD,... Read more

June 19, 2018 Clinical Research/Diagn. M&A, Partnerships

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology

Basel, 19 June 2018 Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer Merger focuses on driving ubiquity of Foundation Medicine’s high... Read more

June 19, 2018 Clinical Research/Diagn. M&A, Partnerships

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology

Basel, 19 June 2018 Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer Merger focuses on driving ubiquity of Foundation Medicine’s high... Read more

June 15, 2018 Product Launch

New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan

Basel, 15 June 2018 New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan After a follow-up time of nearly five years the CLL11 study shows a 51% reduction in the risk of disease progression or death with Gazyva/Gazyvaro compared to MabThera/Rituxan The final analysis reports a... Read more

June 15, 2018 Product Launch

New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan

Basel, 15 June 2018 New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan After a follow-up time of nearly five years the CLL11 study shows a 51% reduction in the risk of disease progression or death with Gazyva/Gazyvaro compared to MabThera/Rituxan The final analysis reports a... Read more

June 14, 2018 Licensing, IP, and Legal Product Launch

Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis

Basel, 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis OCREVUS may delay the need for a wheelchair by seven years for people with primary progressive multiple sclerosis (PPMS) Longer-term efficacy and safety data are consistent... Read more

June 13, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Basel, 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

June 13, 2018 Acad, Gov/Utilities

FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Basel, 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

June 11, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia

Basel, 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the... Read more